We observed no statistically different BC-SS characteristics for IBC patient cases based on HER2 receptor status at the time of diagnosis on unadjusted analysis, and a borderline significantly improved survival for patient cases with HER2+ tumors in the BC-SS adjusted analysis. This evidence concerns the gene ERBB2 and inflammatory breast carcinoma.